查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950447

冠狀動脈介入器材市場（依產品類型、輸送系統、應用、銷售管道和最終用戶分類），全球預測，2026-2032年

Coronary Interventional Devices Market by Product Type, Delivery System, Application, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，冠狀動脈介入器材市場價值將達到 194.5 億美元，到 2026 年將成長至 207.3 億美元，到 2032 年將達到 288.5 億美元，複合年成長率為 5.79%。

關鍵市場統計數據
基準年 2025 194.5億美元
預計年份：2026年 207.3億美元
預測年份 2032 288.5億美元
複合年成長率 (%) 5.79%

本文簡明扼要地描述了臨床需求、人口老化和手術創新如何重塑冠狀動脈介入治療的需求、器械設計和治療路徑。

冠狀動脈介入治療器材是現代冠狀動脈阻塞性疾病患者醫療照護的基礎，它們提供直接的機械和藥物解決方案，以恢復灌注並降低缺血風險。這些技術涵蓋支架、球囊導管和各種動脈粥狀硬化斑塊切除術系統，每種器械根據病變類型、血管大小和手術策略發揮不同的作用。隨著臨床醫生追求更微創、更持久的治療方法，器械的性能、輸送性和與輔助影像和藥物治療的兼容性對於決定手術成功和患者的長期預後至關重要。

技術進步、不斷變化的醫療服務環境以及循證監管要求如何融合，正在重新定義醫療器材的開發和應用路徑

冠狀動脈介入治療領域正經歷變革，這主要得益於技術的成熟、醫療服務模式的轉變以及臨床醫生期望的不斷提高。在技​​術方面，藥物釋放型支架平台不斷改進聚合物化學、藥物釋放動力學和支架幾何結構，以平衡徑向強度和內皮修復。同時，人們對生物可吸收概念和藥物塗層球囊的興趣日益濃厚，推動了新的臨床研究和特定領域的應用，特別是在血管保護和血管再阻塞促進因素需要替代方法的領域。這些器材層面的變革與術中成像技術和生理評估技術的進步相輔相成。高解析度成像和生理引導的工作流程正被擴大用於最佳化器械的選擇和部署，從而降低手術操作的變異性。

評估2025年關稅對冠狀動脈介入器材生態系供應鏈、籌資策略和製造投資決策的影響

預計在2025年前後實施的關稅政策，為冠狀動脈介入器材產業的籌資策略、採購計畫和定價決策引入了新的成本因素。進口關稅和協調關稅分類的變更影響了包括特殊合金、聚合物和精密工程導管零件在內的多種器械組件，給依賴全球一體化供應鏈的製造商帶來了即時的成本壓力。為了因應這些變化，許多公司加快供應商多元化進程，探索近岸外包的機會，並考慮垂直整合方案，以降低進口關稅和運輸成本波動的風險。

深入分析產品、臨床用戶和分銷管道的細分，以揭示不同設備組合的技術權衡、採用促進因素和供應鏈影響。

了解產品和分銷管道的細分，有助於揭示冠狀動脈介入產品領域內臨床需求、技術重點和商業性策略的交匯點。在支架領域，裸金屬支架、生物可吸收血管支架和藥物釋放型支架之間的差異，反映了不同的研發重點。裸金屬支架強調機械結構的簡易性和成本效益，而生物可吸收支架則優先考慮暫時的血管支撐和最終的生物功能恢復。藥物釋放型支架則著重於藥物與聚合物的相互作用以及合金的選擇，其中鈷鉻合金、鉑鉻合金和不銹鋼合金分別代表了輸送性、徑向強度和滲透性方面的權衡。同時，球囊導管的多樣性——從傳統球囊導管到切割球囊球囊導管、藥物塗層球囊導管和折疊球囊導管——反映了針對病變形態進行工具最佳化，以及在鈣化或血管再阻塞部位進行高效藥物輸送和斑塊修飾的需求。

對醫療保健結構和報銷環境的區域差異如何導致採用路徑和商業化策略的差異進行策略性評估

區域趨勢顯著影響臨床實務模式、報銷機制以及技術應用的速度。在美洲，手術量和醫生對先進經皮治療方法的熟悉程度往往有利於高階技術的廣泛應用，而整合的支付系統和大規模的綜合醫療網路則推動了結構化的採購方式和基於價值的合約談判。因此，該地區的市場參與企業正專注於可靠的臨床數據、高效的服務模式以及與醫院集團採購政策相符的夥伴關係。

對主要企業的策略重點進行深入分析，揭示研發投入、通路選擇和供應鏈韌性如何塑造其競爭優勢。

為了滿足臨床需求和應對競爭壓力，業內相關人員正積極尋求結合針對性研發、策略聯盟和生產最佳化等多種策略。領先的心臟器械公司致力於透過金屬合金、聚合物科學和抗增殖劑的進步，提高支架輸送性能、降低血栓形成風險並延長使用壽命。其他公司則透過整合影像平台，並為臨床醫生提供術前規劃和術中決策支援的數位化工具，來完善其核心產品線。在產品創新的同時，多家公司正透過建立區域製造地和採用多種關鍵零件籌資策略，加大對供應鏈韌性的投入。

為商業、臨床和供應鏈領導者提供實用建議，幫助他們將證據和韌性轉化為永續的競爭優勢。

產業領導者應優先採取一系列協作行動，以在控制營運風險的同時，充分發揮臨床價值。首先，產品藍圖必須與已證實的臨床需求和真實世界證據一致。這需要重點投資於註冊登記和上市後監測，將設備特性與以患者為中心的療效和衛生經濟學終點聯繫起來。其次，應透過對替代供應商進行資質認證、提高庫存透明度以及探索區域製造夥伴關係關係來落實供應鏈多元化，從而降低關稅和物流風險。第三，與臨床醫生和手術團隊的密切合作必須超越初始應用階段，涵蓋全面的培訓、指導和數位化支援工具，以提高手術流程的一致性和療效。

採用透明的混合方法調查方法框架，結合臨床醫生訪談、監管數據和註冊分析以及交叉檢驗的證據綜合，為策略決策提供資訊。

本研究採用混合方法，整合冠狀動脈介入領域的技術、臨床和商業性見解。主要資料收集包括對介入性心臟病專家、採購主管和器材技術人員進行結構化訪談，以了解實際操作偏好、庫存管理實務和未滿足的臨床需求。這些定性見解與監管申報文件、同行評審的臨床試驗和手術註冊數據進行三角驗證，以確保與已發表的證據一致，並識別新興的實踐模式。此外，採購和分銷專家提供了有關合約、物流和海關相關影響的營運背景資訊。

對技術創新、臨床參與和營運韌性如何整合以定義冠狀動脈介入治療市場未來成功進行綜合分析

累積分析凸顯了臨床需求與快速創新之間的交會點，在此交會點上，器械設計、手術影像和輸送模式共同決定了病患和購買者的價值。支架技術、輔助球囊和動脈粥狀硬化斑塊切除術的進步正在拓展臨床醫生可用的治療手段，而區域和政策趨勢則影響這些技術的應用速度和特點。在面臨新興關稅挑戰和不斷變化的報銷環境的背景下，供應鏈韌性和實證醫學能力是至關重要的差異化因素。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 冠狀動脈介入器材市場（依產品類型分類）

  • 冠狀動脈支架
    • 裸金屬支架
    • 藥物塗層支架
    • 生物可吸收支架
    • 藥物釋放型支架
  • 球囊導管
    • 預擴張球囊
    • 擴張後球囊
    • 藥物塗層球囊
    • 切割球囊和球囊導管
  • 導管導引線
    • 主力導管導引線
    • 支撐導管導引線
    • 特殊導管導引線
  • 導管
    • 引導管
    • 診斷導管
  • 血管通路及閉合裝置
    • 導入鞘套
    • 止血瓣
    • 血管閉合裝置
  • 斑塊修飾裝置
    • 動脈粥狀硬化斑塊切除術裝置
    • 血管內碎石系統
  • 血栓切除術及栓塞保護裝置
    • 吸食血栓清除裝置
    • 機械血栓切除裝置
    • 栓塞保護裝置
  • 血流動力學輔助裝置
    • 主動脈內球囊反搏泵
    • 經皮心室輔助裝置
  • 影像和生理設備
    • 血管內超音波系統
    • 光同調斷層掃瞄系統
    • 分數血流儲備測量系統
    • 瞬時波形自由比率測量系統

9. 依輸送系統分類的冠狀動脈介入器材市場

  • 越過電線
  • 快速交換
  • 固定電線
  • 可轉向系統
  • 鞘套系統

第10章：冠狀動脈介入器材市場（依應用領域分類）

  • 穩定性冠狀動脈疾病
  • 急性冠狀動脈症候群
    • ST段上升型心肌梗塞
    • 非ST段上升型急性冠狀動脈症候群
  • 慢性完全閉塞
  • 左主幹病變
  • 分叉病變
  • 支架內血管再阻塞

第11章：冠狀動脈介入器材市場（依銷售管道分類）

  • 直銷
  • 透過分銷商銷售
  • 線上採購平台

12. 依最終使用者分類的冠狀動脈介入器材市場

  • 醫院
  • 心臟導管檢查室
  • 門診手術中心

13. 冠狀動脈介入器材市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：冠狀動脈介入器材市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國冠狀動脈介入器材市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國冠狀動脈介入器材市場

17. 中國：冠狀動脈介入器材市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • B. Braun Melsungen AG
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cardiovascular Systems, Inc.
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Elixir Medical Corporation
  • Endologix LLC
  • iVascular SLU
  • Johnson & Johnson Services, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • QualiMed Innovative Medizinprodukte GmbH
  • Sahajanand Medical Technologies Limited
  • Shockwave Medical, Inc.
  • Siemens Healthineers AG
  • Teleflex Incorporated
  • Terumo Corporation
Product Code: MRR-4F7A6D4FD86D

The Coronary Interventional Devices Market was valued at USD 19.45 billion in 2025 and is projected to grow to USD 20.73 billion in 2026, with a CAGR of 5.79%, reaching USD 28.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.45 billion
Estimated Year [2026] USD 20.73 billion
Forecast Year [2032] USD 28.85 billion
CAGR (%) 5.79%

A concise portrayal of how clinical needs, aging populations, and procedural innovation are reshaping demand, device design, and care pathways in coronary interventions

Coronary interventional devices form the backbone of contemporary care for patients with obstructive coronary artery disease, providing direct mechanical and pharmacologic solutions that restore perfusion and reduce ischemic risk. These technologies span stents, balloon catheters, and a spectrum of atherectomy systems, each playing a distinct role across lesion types, vessel sizes, and procedural strategies. As clinicians pursue less invasive, more durable interventions, device performance, deliverability, and compatibility with adjunctive imaging and pharmacotherapy have become central determinants of procedural success and longer-term patient outcomes.

Epidemiologically, the prevalence of coronary artery disease remains elevated in many middle- and high-income populations, driven by aging demographics and persistent cardiometabolic risk factors. Consequently, the procedural mix is evolving: there is greater emphasis on complex lesion management, including calcified and bifurcation disease, which increases the demand for specialized devices and hybrid approaches. Simultaneously, shifts in care settings-from inpatient catheterization laboratories toward ambulatory surgical centers-are influencing device selection, inventory models, and logistics. These converging clinical, demographic, and care-delivery trends set the stage for rapid innovation and strategic recalibration among device manufacturers, health systems, and distributors.

From a regulatory and clinical-evidence perspective, iterative enhancements in device materials, drug elution platforms, and scaffold constructs have lowered complication rates and expanded indication envelopes. Emerging imaging modalities and physiology-driven decision tools are reshaping procedural algorithms, prompting device makers to integrate compatibility and adjunctive support into product roadmaps. Taken together, these factors underscore a dynamic environment in which clinical efficacy, economic value, and supply chain resilience define competitive differentiation.

How converging technological advancements, care setting migration, and evidence-driven regulatory expectations are redefining device development and adoption pathways

The coronary interventional landscape is being transformed by a confluence of technological maturation, shifting care delivery models, and evolving clinician expectations. On the technology front, drug eluting stent platforms continue to refine polymer chemistry, drug-release kinetics, and strut geometry to balance radial strength with endothelial healing. Concurrently, interest in bioresorbable concepts and drug-coated balloons has stimulated new clinical investigations and niche adoption where vessel preservation or restenosis biology warrants alternative approaches. These device-level shifts are complemented by advances in intraprocedural imaging and physiologic assessment; high-resolution imaging and physiology-guided workflows are increasingly used to optimize device selection and deployment, thereby reducing procedural variability.

Care delivery transformations are equally consequential. The migration of lower-risk percutaneous procedures to ambulatory surgical centers and specialty clinics is altering device procurement cycles, inventory strategies, and sterile processing requirements. As a result, manufacturers and distributors must prioritize compact packaging, rapid order fulfillment, and training resources tailored to diverse clinical environments. In parallel, digital health innovations-ranging from procedure planning software to remote proctoring-are enabling virtual training and performance feedback loops that accelerate clinician adoption of new devices. This digital integration also supports post-market surveillance and real-world evidence generation, which in turn inform iterative product improvements.

Finally, regulatory expectations and payer scrutiny are influencing product development strategies. There is stronger emphasis on demonstrable value, long-term safety, and comparative effectiveness, driving manufacturers to invest in both rigorous clinical programs and longitudinal registries. Taken together, these transformative shifts are forging a more connected ecosystem in which technical innovation, evidence generation, and delivery-channel optimization co-evolve to define competitive advantage.

An assessment of how 2025 tariff measures reshaped supply chains, procurement strategies, and manufacturing investment decisions across the coronary device ecosystem

Tariff policy enacted in and around 2025 introduced new cost considerations that ripple through sourcing strategies, procurement planning, and pricing decisions in the coronary interventional device space. Import duties and changes in harmonized tariff classifications affected a range of device components, including specialized alloys, polymeric compounds, and precision-engineered catheter elements, creating immediate cost pressure for manufacturers reliant on globalized supply chains. In response, many firms accelerated supplier diversification, sought nearshoring opportunities, and examined vertical integration options to reduce exposure to import levies and shipping volatility.

Beyond direct input-cost effects, tariffs influenced partner negotiations and distribution economics. Distributors with long-standing contracts adjusted margin structures to accommodate higher landed costs, while health systems re-evaluated formulary choices in light of total cost of ownership. These dynamics encouraged some purchasers to favor devices with simplified supply chains or to negotiate bundled pricing that encompassed ancillary disposables. Moreover, tariffs affected innovation timelines: capital that might have funded incremental R&D or commercialization activities in low-margin product lines was redirected to securing supply continuity and manufacturing resilience.

Crucially, the policy environment also catalyzed strategic investments in domestic manufacturing capabilities and quality-system enhancements. Firms investing in local production faced higher upfront costs but gained shorter lead times and greater control over regulatory compliance and traceability. As a result, an important consequence of tariff-induced disruption was a reconfiguration of risk management priorities across the industry, with procurement resilience, supplier transparency, and operational flexibility moving to the top of executive agendas.

Deep dive into product, clinical-user, and distribution segmentation that clarifies engineering trade-offs, adoption drivers, and supply chain implications for device portfolios

Understanding product and channel segmentation reveals where clinical demand, engineering focus, and commercial effort converge within coronary interventional portfolios. In the stent arena, distinctions among bare metal stent, bioresorbable vascular scaffold, and drug eluting stent illuminate divergent development priorities: bare metal constructs emphasize mechanical simplicity and cost-efficiency, whereas bioresorbable scaffolds prioritize temporary vessel support and eventual restoration of native physiology; drug eluting stents concentrate on drug-polymer interactions and alloy choice, with cobalt chromium, platinum chromium, and stainless steel variants each representing trade-offs in deliverability, radial strength, and radiopacity. Meanwhile, balloon catheter diversity-ranging from conventional balloon catheter designs through cutting balloon catheter, drug coated balloon catheter, and scoring balloon catheter-reflects the need to tailor tools to lesion morphology and to optimize drug transfer or plaque modification in calcified or restenotic segments.

Complementing stents and balloons, the atherectomy system segment is defined by distinct mechanistic approaches: laser atherectomy system solutions ablate tissue with precision energy, orbital atherectomy systems modify calcific plaque through centrifugal sanding, and rotational atherectomy systems selectively remove hard plaque using high-speed burrs. These modalities are selected based on lesion calcification patterns, vessel tortuosity, and operator familiarity, which in turn influences training and capital equipment strategies. From a user perspective, differences among ambulatory surgical centers, hospitals, and specialty clinics drive procurement behavior, procedural throughput expectations, and inventory management. Ambulatory settings typically emphasize disposability, rapid turnover, and compact sterile inventories, while hospitals balance a broader device mix with integrated support services; specialty clinics occupy niche positions where highly specialized devices and expertise are concentrated.

Distribution channels-direct relationships, distributor partnerships, and online ordering pathways-also determine market reach and service models. Manufacturers relying on direct sales often invest heavily in clinical education and local field teams, whereas distributor networks provide broad geographic coverage and logistical scalability; online channels add convenience and traceability but require robust quality assurances and regulatory vetting. Taken together, these segmentation layers animate product strategy, clinical engagement, and commercial execution across the coronary interventional landscape.

A strategic appraisal of how distinct regional healthcare structures and reimbursement environments drive differentiated adoption paths and commercialization tactics

Regional dynamics shape clinical practice patterns, reimbursement realities, and the pace of technology adoption in notable ways. In the Americas, procedural volumes and physician familiarity with advanced percutaneous solutions tend to support broad uptake of premium technologies, while consolidated payer systems and large integrated delivery networks drive structured procurement approaches and value-based contracting discussions. As a consequence, market entrants in this region focus on robust clinical data, efficient service models, and partnerships that align with hospital group procurement preferences.

Across Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable reimbursement pathways create a complex adoption landscape. While several European markets rapidly embrace evidence-backed innovations, other countries within the region prioritize cost-containment, which requires flexible pricing strategies and local reimbursement evidence. In addition, several nations within the region are implementing national registries and quality benchmarks that influence clinician adoption patterns and post-market surveillance expectations.

In Asia-Pacific, rising demand is propelled by expanding access to advanced cardiovascular care, increasing urbanization, and growing capacity in tertiary care centers. However, the region is not monolithic: advanced health systems in some economies demonstrate rapid uptake of next-generation devices, while emerging markets emphasize affordability and simplified logistics. Consequently, manufacturers pursuing Asia-Pacific expansion must calibrate product offerings to local clinical needs, regulatory timelines, and distribution capabilities, and they often combine clinical partnerships with localized training programs to build adoption momentum.

Insightful exploration of leading firms' strategic priorities showing how R&D focus, channel choices, and supply resilience are shaping competitive advantage

Industry participants are responding to clinical demand and competitive pressures through a combination of targeted R&D, strategic partnerships, and manufacturing optimization. Leading cardiac device companies have concentrated on enhancing stent deliverability, reducing thrombogenicity, and extending durability through advances in metallic alloys, polymer science, and antiproliferative agents. Others have supplemented core product lines by integrating imaging-compatible platforms and by supporting clinicians with digital tools for pre-procedural planning and intraoperative decision support. Parallel to product innovation, several firms have invested in supply-chain resilience by establishing regional manufacturing sites and by adopting multi-sourcing strategies for critical components.

Competitive dynamics also reflect differing go-to-market approaches. Some companies prioritize direct clinical engagement and long-term hospital partnerships, deploying dedicated field clinical specialists and robust training curricula to secure premium placements. Meanwhile, others leverage distributor networks and e-commerce channels to reach broader geographies and smaller care settings. Alliances between device manufacturers and technology firms are emerging, particularly in areas that link procedural devices with software-driven analytics and post-market surveillance capabilities. These collaborations aim to generate real-world evidence more efficiently and to support differentiated value propositions in reimbursement negotiations.

Collectively, company-level strategies reveal an industry balancing near-term operational resilience with longer-term innovation pipelines, translating scientific advances into reproducible clinical outcomes and scalable commercial models.

Action-focused recommendations for commercial, clinical, and supply-chain leaders to convert evidence and resilience into sustainable competitive advantage

Industry leaders should prioritize a set of coordinated actions to capture clinical value while managing operational risk. First, aligning product roadmaps with demonstrated clinical need and real-world evidence will be essential; this requires concentrated investment in registries and post-market studies that link device characteristics to patient-centered outcomes and health economic endpoints. Second, companies should operationalize supply-chain diversification by qualifying alternate suppliers, increasing inventory transparency, and exploring regional manufacturing partnerships to mitigate tariff and logistics risks. Third, close collaboration with clinicians and procedural teams must expand beyond initial product adoption to include comprehensive training, proctoring, and digital support tools that improve procedural consistency and outcomes.

Additionally, commercial teams should refine segmentation strategies to match distribution and pricing models with care settings-adapting packaging, service bundles, and procurement terms for ambulatory surgical centers, hospitals, and specialty clinics. Strategic partnerships with payers and health systems to develop outcome-based or bundled payment pilots can accelerate uptake for high-value technologies. Finally, leaders must invest in data capabilities that capture real-world performance, enabling iterative product improvements and stronger payer dialogues. By executing on these prioritized actions, organizations can strengthen clinical credibility, reduce exposure to external shocks, and accelerate sustainable growth.

A transparent mixed-methods research framework combining clinician interviews, regulatory and registry analyses, and cross-validated evidence synthesis to inform strategic decisions

The research adopted a mixed-methods approach to synthesize technical, clinical, and commercial insights across the coronary interventional domain. Primary data collection included structured interviews with interventional cardiologists, procurement leads, and device engineers to capture real-world procedural preferences, inventory practices, and unmet clinical needs. These qualitative inputs were triangulated with regulatory filings, peer-reviewed clinical trials, and procedural registry data to ensure alignment with published evidence and to identify emergent practice patterns. In addition, procurement and distribution experts provided operational context on contracting, logistics, and tariff-related impacts.

Analytical rigor was maintained through cross-validation of findings across multiple data sources, iterative hypothesis testing with subject-matter experts, and sensitivity checks where available. The methodology emphasized transparency in source attribution, explicit acknowledgment of regional heterogeneity, and a focus on outcome-relevant metrics rather than proprietary market sizing. Limitations include variable data granularity across regions and the evolving nature of regulatory decisions that may alter adoption timelines. To mitigate these constraints, the study prioritized longitudinal evidence and expert consensus to produce robust, actionable conclusions intended to inform strategic planning and operational decision-making.

Synthesis of how technological advances, clinical engagement, and operational resilience converge to define future success across coronary intervention markets

The cumulative analysis underscores a sector at the intersection of clinical necessity and rapid innovation, where device design, procedural imaging, and care-delivery models collectively determine value for patients and purchasers. Advances in stent technology, adjunctive balloons, and atherectomy modalities are expanding the armamentarium available to clinicians, while regional and policy dynamics shape the speed and character of adoption. Supply-chain resilience and evidence-generation capabilities have become decisive differentiators, particularly in an environment that includes new tariff considerations and variable reimbursement landscapes.

As the industry moves forward, successful stakeholders will be those who translate scientific progress into replicable clinical benefit, who align commercial models with diverse care settings, and who invest in resilient operations. Continuous engagement with clinicians, payers, and regulatory authorities will be essential to ensure that innovations meet both clinical and economic criteria for broad adoption. Ultimately, the path to sustained impact lies in pairing rigorous evidence with adaptable commercialization strategies that respect regional realities and evolving procedural practices.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coronary Interventional Devices Market, by Product Type

  • 8.1. Coronary Stents
    • 8.1.1. Bare Metal Stents
    • 8.1.2. Drug Eluting Stents
    • 8.1.3. Bioresorbable Scaffolds
    • 8.1.4. Drug Coated Stents
  • 8.2. Balloon Catheters
    • 8.2.1. Pre Dilatation Balloons
    • 8.2.2. Post Dilatation Balloons
    • 8.2.3. Drug Coated Balloons
    • 8.2.4. Cutting And Scoring Balloons
  • 8.3. Guidewires
    • 8.3.1. Workhorse Guidewires
    • 8.3.2. Support Guidewires
    • 8.3.3. Specialty Guidewires
  • 8.4. Catheters
    • 8.4.1. Guiding Catheters
    • 8.4.2. Diagnostic Catheters
  • 8.5. Vascular Access And Closure Devices
    • 8.5.1. Introducer Sheaths
    • 8.5.2. Hemostatic Valves
    • 8.5.3. Vascular Closure Devices
  • 8.6. Plaque Modification Devices
    • 8.6.1. Atherectomy Devices
    • 8.6.2. Intravascular Lithotripsy Systems
  • 8.7. Thrombectomy And Embolic Protection Devices
    • 8.7.1. Aspiration Thrombectomy Devices
    • 8.7.2. Mechanical Thrombectomy Devices
    • 8.7.3. Embolic Protection Devices
  • 8.8. Hemodynamic Support Devices
    • 8.8.1. Intra Aortic Balloon Pumps
    • 8.8.2. Percutaneous Ventricular Assist Devices
  • 8.9. Imaging And Physiology Devices
    • 8.9.1. Intravascular Ultrasound Systems
    • 8.9.2. Optical Coherence Tomography Systems
    • 8.9.3. Fractional Flow Reserve Systems
    • 8.9.4. Instantaneous Wave Free Ratio Systems

9. Coronary Interventional Devices Market, by Delivery System

  • 9.1. Over The Wire
  • 9.2. Rapid Exchange
  • 9.3. Fixed Wire
  • 9.4. Steerable Systems
  • 9.5. Sheathless Systems

10. Coronary Interventional Devices Market, by Application

  • 10.1. Stable Coronary Artery Disease
  • 10.2. Acute Coronary Syndromes
    • 10.2.1. ST Elevation Myocardial Infarction
    • 10.2.2. Non ST Elevation Acute Coronary Syndromes
  • 10.3. Chronic Total Occlusion
  • 10.4. Left Main Disease
  • 10.5. Bifurcation Lesions
  • 10.6. In Stent Restenosis

11. Coronary Interventional Devices Market, by Sales Channel

  • 11.1. Direct Sales
  • 11.2. Distributor Sales
  • 11.3. Online Procurement Platforms

12. Coronary Interventional Devices Market, by End User

  • 12.1. Hospitals
  • 12.2. Cardiac Catheterization Laboratories
  • 12.3. Ambulatory Surgical Centers

13. Coronary Interventional Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Coronary Interventional Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Coronary Interventional Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Coronary Interventional Devices Market

17. China Coronary Interventional Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AngioDynamics, Inc.
  • 18.7. B. Braun Melsungen AG
  • 18.8. Biotronik SE & Co. KG
  • 18.9. Boston Scientific Corporation
  • 18.10. Cardinal Health, Inc.
  • 18.11. Cardiovascular Systems, Inc.
  • 18.12. Cook Medical LLC
  • 18.13. Edwards Lifesciences Corporation
  • 18.14. Elixir Medical Corporation
  • 18.15. Endologix LLC
  • 18.16. iVascular S.L.U.
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Lepu Medical Technology (Beijing) Co., Ltd.
  • 18.19. Medtronic plc
  • 18.20. Merit Medical Systems, Inc.
  • 18.21. MicroPort Scientific Corporation
  • 18.22. QualiMed Innovative Medizinprodukte GmbH
  • 18.23. Sahajanand Medical Technologies Limited
  • 18.24. Shockwave Medical, Inc.
  • 18.25. Siemens Healthineers AG
  • 18.26. Teleflex Incorporated
  • 18.27. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CORONARY INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRE DILATATION BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRE DILATATION BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRE DILATATION BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY POST DILATATION BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY POST DILATATION BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY POST DILATATION BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY WORKHORSE GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY WORKHORSE GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY WORKHORSE GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUPPORT GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUPPORT GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUPPORT GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDING CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDING CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDING CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRODUCER SHEATHS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRODUCER SHEATHS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRODUCER SHEATHS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMOSTATIC VALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMOSTATIC VALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMOSTATIC VALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR CLOSURE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR CLOSURE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR CLOSURE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ATHERECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ATHERECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR LITHOTRIPSY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR LITHOTRIPSY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR LITHOTRIPSY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRA AORTIC BALLOON PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRA AORTIC BALLOON PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRA AORTIC BALLOON PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INSTANTANEOUS WAVE FREE RATIO SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INSTANTANEOUS WAVE FREE RATIO SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INSTANTANEOUS WAVE FREE RATIO SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OVER THE WIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OVER THE WIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OVER THE WIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY RAPID EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY RAPID EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY RAPID EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FIXED WIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FIXED WIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FIXED WIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STEERABLE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STEERABLE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STEERABLE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SHEATHLESS SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SHEATHLESS SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SHEATHLESS SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY NON ST ELEVATION ACUTE CORONARY SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY NON ST ELEVATION ACUTE CORONARY SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY NON ST ELEVATION ACUTE CORONARY SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY LEFT MAIN DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY LEFT MAIN DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY LEFT MAIN DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIFURCATION LESIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIFURCATION LESIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIFURCATION LESIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IN STENT RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IN STENT RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IN STENT RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ONLINE PROCUREMENT PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ONLINE PROCUREMENT PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ONLINE PROCUREMENT PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 269. MID